Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 5/2011

01-10-2011 | Review

Signal transducer and activator of transcription 5 as a key signaling pathway in normal mammary gland developmental biology and breast cancer

Authors: Priscilla A Furth, Rebecca E Nakles, Sarah Millman, Edgar S Diaz-Cruz, M Carla Cabrera

Published in: Breast Cancer Research | Issue 5/2011

Login to get access

Abstract

STAT5 consists of two proteins, STAT5A/B, that impact mammary cell differentiation, proliferation, and survival. In normal development, STAT5 expression and activity are regulated by prolactin signaling with JAK2/ELF5, EGF signaling networks that include c-Src, and growth hormone, insulin growth factor, estrogen, and progesterone signaling pathways. In cancer, erythropoietin signaling can also regulate STAT5. Activation levels are influenced by AKT, caveolin, PIKE-A, Pak1, c-Myb, Brk, beta-integrin, dystroglycan, other STATs, and STAT pathway molecules JAK1, Shp2, and SOCS. TGF-β and PTPN9 can downregulate prolactin- and EGF-mediated STAT5 activation, respectively. IGF, AKT, RANKL, cyclin D1, BCL6, and HSP90A lie downstream of STAT5.
Appendix
Available only for authorised users
Literature
1.
Hennighausen L, Robinson GW: Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev. 2008, 22: 711-721. 10.1101/gad.1643908.CrossRefPubMedPubMedCentral
2.
Desrivieres S, Kunz C, Barash I, Vafaizadeh V, Borghouts C, Groner B: The Biological Functions of the Versatile Transcription Factors STAT3 and STAT5 and New Strategies for their Targeted Inhibition. J Mammary Gland Biol Neoplasia. 2006, 11: 75-87. 10.1007/s10911-006-9014-4.CrossRefPubMed
3.
Ferbeyre G, Moriggl R: The role of Stat5 transcription factors as tumor suppressors or oncogenes. Biochim Biophys Acta. 2011, 1815: 104-114.PubMed
4.
Silva CM: Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene. 2004, 23: 8017-8023. 10.1038/sj.onc.1208159.CrossRefPubMed
5.
Liu X, Robinson GW, Gouilleux F, Groner B, Hennighausen L: Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc Natl Acad Sci USA. 1995, 92: 8831-8835. 10.1073/pnas.92.19.8831.CrossRefPubMedPubMedCentral
6.
Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L: Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 1997, 11: 179-186. 10.1101/gad.11.2.179.CrossRefPubMed
7.
Hennighausen L, Robinson GW, Wagner KU, Liu X: Developing a mammary gland is a stat affair. J Mammary Gland Biol Neoplasia. 1997, 2: 365-372. 10.1023/A:1026347313096.CrossRefPubMed
8.
Li M, Liu X, Robinson G, Bar-Peled U, Wagner KU, Young WS, Hennighausen L, Furth PA: Mammary-derived signals activate programmed cell death during the first stage of mammary gland involution. Proc Natl Acad Sci USA. 1997, 94: 3425-3430. 10.1073/pnas.94.7.3425.CrossRefPubMedPubMedCentral
9.
Liu X, Gallego MI, Smith GH, Robinson GW, Hennighausen L: Functional rescue of Stat5a-null mammary tissue through the activation of compensating signals including Stat5b. Cell Growth Differ. 1998, 9: 795-803.PubMed
10.
Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, Waxman DJ, Davey HW: Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci USA. 1997, 94: 7239-7244. 10.1073/pnas.94.14.7239.CrossRefPubMedPubMedCentral
11.
Pontillo C, Garcia M, Pena D, Cocca C, Chiappini F, Alvarez L, Kleiman de Pisarev D, Randi A: Activation of c-Src/HER1/STAT5b and HER1/ERK1/2 signaling pathways and cell migration by hexachlorobenzene in MDAMB-231 human breast cancer cell line. Toxicol Sci. 2011, 120: 284-296. 10.1093/toxsci/kfq390.CrossRefPubMed
12.
Lim E-J, Joung Y-H, Jung S-M, Park SH, Park JH, Kim SY, Hwang TS, Hong DY, Chung SC, Ye S-K, Moon E-S, Park EU, Park T, Chung I-M, Yang YM: Hemin inhibits cyclin D1 and IGF-1 expression via STAT5b under hypoxia in ERalpha-negative MDA-MB 231 breast cancer cells. Int J Oncol. 2010, 36: 1243-1251.PubMed
13.
Tang J-Z, Zuo Z-H, Kong X-J, Steiner M, Yin Z, Perry JK, Zhu T, Liu D-X, Lobie PE: Signal transducer and activator of transcription (STAT)-5A and STAT5B differentially regulate human mammary carcinoma cell behavior. Endocrinology. 2010, 151: 43-55. 10.1210/en.2009-0651.CrossRefPubMed
14.
Bernaciak TM, Zareno J, Parsons JT, Silva CM: A novel role for signal transducer and activator of transcription 5b (STAT5b) in beta1-integrinmediated human breast cancer cell migration. Breast Cancer Res. 2009, 11: R52-10.1186/bcr2341.CrossRefPubMedPubMedCentral
15.
Joung Y-H, Lim E-J, Kim M-S, Lim SD, Yoon S-Y, Lim YC, Yoo YB, Ye S-K, Park T, Chung I-M, Bae K-Y, Yang YM: Enhancement of hypoxia-induced apoptosis of human breast cancer cells via STAT5b by momilactone B. Int J Oncol. 2008, 33: 477-484.PubMed
16.
Fox EM, Bernaciak TM, Wen J, Weaver AM, Shupnik MA, Silva CM: Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells. Mol Endocrinol. 2008, 22: 1781-1796. 10.1210/me.2007-0419.CrossRefPubMedPubMedCentral
17.
Tan SH, Nevalainen MT: Signal transducer and activator of transcription 5A/B in prostate and breast cancers. Endocr Relat Cancer. 2008, 15: 367-390. 10.1677/ERC-08-0013.CrossRefPubMed
18.
Wang R-A, Vadlamudi RK, Bagheri-Yarmand R, Beuvink I, Hynes NE, Kumar R: Essential functions of p21-activated kinase 1 in morphogenesis and differentiation of mammary glands. J Cell Biol. 2003, 161: 583-592. 10.1083/jcb.200212066.CrossRefPubMedPubMedCentral
19.
Johnson KJ, Peck AR, Liu C, Tran TH, Utama FE, Sjolund AB, Schaber JD, Witkiewicz AK, Rui H: PTP1B suppresses prolactin activation of Stat5 in breast cancer cells. Am J Pathol. 2010, 177: 2971-2983. 10.2353/ajpath.2010.090399.CrossRefPubMedPubMedCentral
20.
Wagner KU, Rui H: Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression. J Mammary Gland Biol Neoplasia. 2008, 13: 93-103. 10.1007/s10911-008-9062-z.CrossRefPubMed
21.
Yamaji D, Na R, Feuermann Y, Pechhold S, Chen W, Robinson GW, Hennighausen L: Development of mammary luminal progenitor cells is controlled by the transcription factor STAT5A. Genes Dev. 2009, 23: 2382-2387. 10.1101/gad.1840109.CrossRefPubMedPubMedCentral
22.
Bernichtein S, Touraine P, Goffin V: New concepts in prolactin biology. J Endocrinol. 2010, 206: 1-11. 10.1677/JOE-10-0069.CrossRefPubMed
23.
Arendt LM, Evans LC, Rugowski DE, Garcia-Barchino MJ, Rui H, Schuler LA: Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes. J Endocrinol. 2009, 203: 99-110. 10.1677/JOE-09-0221.CrossRefPubMedPubMedCentral
24.
Arendt LM, Rugowski DE, Grafwallner-Huseth TA, Garcia-Barchino MJ, Rui H, Schuler LA: Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. Breast Cancer Res. 2011, 13: R11-10.1186/bcr2819.CrossRefPubMedPubMedCentral
25.
Kelly PA, Bachelot A, Kedzia C, Hennighausen L, Ormandy CJ, Kopchick JJ, Binart N: The role of prolactin and growth hormone in mammary gland development. Mol Cell Endocrinol. 2002, 197: 127-131. 10.1016/S0303-7207(02)00286-1.CrossRefPubMed
26.
Neilson LM, Zhu J, Xie J, Malabarba MG, Sakamoto K, Wagner K-U, Kirken RA, Rui H: Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways. Mol Endocrinol. 2007, 21: 2218-2232. 10.1210/me.2007-0173.CrossRefPubMed
27.
Watkin H, Richert MM, Lewis A, Terrell K, McManaman JP, Anderson SM: Lactation failure in Src knockout mice is due to impaired secretory activation. BMC Dev Biol. 2008, 8: 6-10.1186/1471-213X-8-6.CrossRefPubMedPubMedCentral
28.
Fox EM, Andrade J, Shupnik MA: Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways. Steroids. 2009, 74: 622-627. 10.1016/j.steroids.2008.10.014.CrossRefPubMed
29.
Garcia-Martinez JM, Calcabrini A, Gonzalez L, Martin-Forero E, Agullo-Ortuno MT, Simon V, Watkin H, Anderson SM, Roche S, Martin-Perez J: A non-catalytic function of the Src family tyrosine kinases controls prolactin-induced Jak2 signaling. Cell Signal. 2010, 22: 415-426. 10.1016/j.cellsig.2009.10.013.CrossRefPubMed
30.
Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang C-Y, Li Y, Li X, Chen C-T, Mills GB, Hortobagyi GN, Mendelsohn J, Hung M-C, Fan Z: Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell. 2010, 18: 423-435. 10.1016/j.ccr.2010.10.025.CrossRefPubMedPubMedCentral
31.
Groner B, Hynes NE: Unfavorable drug interactions in targeted breast cancer therapy. Cancer Cell. 2010, 18: 401-402. 10.1016/j.ccr.2010.10.027.CrossRefPubMed
32.
Gallego MI, Binart N, Robinson GW, Okagaki R, Coschigano KT, Perry J, Kopchick JJ, Oka T, Kelly PA, Hennighausen L: Prolactin, growth hormone, and epidermal growth factor activate Stat5 in different compartments of mammary tissue and exert different and overlapping developmental effects. Dev Biol. 2001, 229: 163-175. 10.1006/dbio.2000.9961.CrossRefPubMed
33.
Tvorogov D, Sundvall M, Kurppa K, Hollmen M, Repo S, Johnson MS, Elenius K: Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer. J Biol Chem. 2009, 284: 5582-5591.CrossRefPubMed
34.
Yang S, Raymond-Stintz MA, Ying W, Zhang J, Lidke DS, Steinberg SL, Williams L, Oliver JM, Wilson BS: Mapping ErbB receptors on breast cancer cell membranes during signal transduction. J Cell Sci. 2007, 120: 2763-2773. 10.1242/jcs.007658.CrossRefPubMed
35.
Jones FE, Welte T, Fu XY, Stern DF: ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation. J Cell Biol. 1999, 147: 77-88. 10.1083/jcb.147.1.77.CrossRefPubMedPubMedCentral
36.
Himpe E, Kooijman R: Insulin-like growth factor-I receptor signal transduction and the Janus Kinase/Signal Transducer and Activator of Transcription (JAK-STAT) pathway. Biofactors. 2009, 35: 76-81. 10.1002/biof.20.CrossRefPubMed
37.
Wood CE, Register TC, Cline JM: Transcriptional profiles of progestogen effects in the postmenopausal breast. Breast Cancer Res Treat. 2009, 114: 233-242. 10.1007/s10549-008-0003-8.CrossRefPubMed
38.
Lange CA, Richer JK, Shen T, Horwitz KB: Convergence of progesterone and epidermal growth factor signaling in breast cancer. Potentiation of mitogen-activated protein kinase pathways. J Biol Chem. 1998, 273: 31308-31316. 10.1074/jbc.273.47.31308.CrossRefPubMed
39.
Santos SJ, Haslam SZ, Conrad SE: Estrogen and progesterone are critical regulators of Stat5a expression in the mouse mammary gland. Endocrinology. 2008, 149: 329-338.CrossRefPubMed
40.
Petersen H, Haldosen LA: EGF modulates expression of STAT5 in mammary epithelial cells. Exp Cell Res. 1998, 243: 347-358. 10.1006/excr.1998.4160.CrossRefPubMed
41.
Menzies KK, Lee HJ, Lefevre C, Ormandy CJ, Macmillan KL, Nicholas KR: Insulin, a key regulator of hormone responsive milk protein synthesis during lactogenesis in murine mammary explants. Funct Integr Genomics. 2010, 10: 87-95. 10.1007/s10142-009-0140-0.CrossRefPubMed
42.
Choi YS, Chakrabarti R, Escamilla-Hernandez R, Sinha S: Elf5 conditional knockout mice reveal its role as a master regulator in mammary alveolar development: failure of Stat5 activation and functional differentiation in the absence of Elf5. Dev Biol. 2009, 329: 227-241. 10.1016/j.ydbio.2009.02.032.CrossRefPubMed
43.
Miermont AM, Parrish AR, Furth PA: Role of ERalpha in the differential response of Stat5a loss in susceptibility to mammary preneoplasia and DMBA-induced carcinogenesis. Carcinogenesis. 2010, 31: 1124-1131. 10.1093/carcin/bgq048.CrossRefPubMedPubMedCentral
44.
Boerner JL, Gibson MA, Fox EM, Posner ED, Parsons SJ, Silva CM, Shupnik MA: Estrogen negatively regulates epidermal growth factor (EGF)-mediated signal transducer and activator of transcription 5 signaling in human EGF family receptor-overexpressing breast cancer cells. Mol Endocrinol. 2005, 19: 2660-2670. 10.1210/me.2004-0439.CrossRefPubMed
45.
Bjornstrom L, Kilic E, Norman M, Parker MG, Sjoberg M: Cross-talk between Stat5b and estrogen receptor-alpha and -beta in mammary epithelial cells. J Mol Endocrinol. 2001, 27: 93-106. 10.1677/jme.0.0270093.CrossRefPubMed
46.
Buser AC, Gass-Handel EK, Wyszomierski SL, Doppler W, Leonhardt SA, Schaack J, Rosen JM, Watkin H, Anderson SM, Edwards DP: Progesterone receptor repression of prolactin/signal transducer and activator of transcription 5-mediated transcription of the beta-casein gene in mammary epithelial cells. Mol Endocrinol. 2007, 21: 106-125.CrossRefPubMed
47.
Bertucci PY, Quaglino A, Pozzi AG, Kordon EC, Pecci A: Glucocorticoidinduced impairment of mammary gland involution is associated with STAT5 and STAT3 signaling modulation. Endocrinology. 2010, 151: 5730-5740. 10.1210/en.2010-0517.CrossRefPubMed
48.
Rocha-Viegas L, Vicent GP, Barañao JL, Beato M, Pecci A: Glucocorticoids repress bcl-X expression in lymphoid cells by recruiting STAT5B to the P4 promoter. J Biol Chem. 2006, 281: 33959-33970. 10.1074/jbc.M602408200.CrossRefPubMed
49.
Litterst CM, Kliem S, Marilley D, Pfitzner E: NCoA-1/SRC-1 is an essential coactivator of STAT5 that binds to the FDL motif in the alpha-helical region of the STAT5 transactivation domain. J Biol Chem. 2003, 278: 45340-45351. 10.1074/jbc.M303644200.CrossRefPubMed
50.
Cella N, Groner B, Hynes NE: Characterization of Stat5a and Stat5b homodimers and heterodimers and their association with the glucocortiocoid receptor in mammary cells. Mol Cell Biol. 1998, 18: 1783-1792.CrossRefPubMedPubMedCentral
51.
Chan C-B, Liu X, Ensslin MA, Dillehay DL, Ormandy CJ, Sohn P, Serra R, Ye K: PIKE-A is required for prolactin-mediated STAT5a activation in mammary gland development. EMBO J. 2010, 29: 956-968. 10.1038/emboj.2009.406.CrossRefPubMedPubMedCentral
52.
Chen CC, Boxer RB, Stairs DB, Portocarrero CP, Horton RH, Alvarez JV, Birnbaum MJ, Chodosh LA: Akt is required for Stat5 activation and mammary differentiation. Breast Cancer Res. 2010, 12: R72-10.1186/bcr2640.CrossRefPubMedPubMedCentral
53.
Fang F, Rycyzyn MA, Clevenger CV: Role of c-Myb during prolactin-induced signal transducer and activator of transcription 5a signaling in breast cancer cells. Endocrinology. 2009, 150: 1597-1606. 10.1210/en.2008-1079.CrossRefPubMed
54.
Ikeda O, Mizushima A, Sekine Y, Yamamoto C, Muromoto R, Nanbo A, Oritani K, Yoshimura A, Matsuda T: Involvement of STAP-2 in Brk-mediated phosphorylation and activation of STAT5 in breast cancer cells. Cancer Sci. 2011, 102: 756-761. 10.1111/j.1349-7006.2010.01842.x.CrossRefPubMed
55.
Sotgia F, Williams TM, Schubert W, Medina F, Minetti C, Pestell RG, Lisanti MP: Caveolin-1 deficiency (-/-) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness. Am J Pathol. 2006, 168: 292-309. 10.2353/ajpath.2006.050429.CrossRefPubMedPubMedCentral
56.
Davey HW, Xie T, McLachlan MJ, Wilkins RJ, Waxman DJ, Grattan DR: STAT5b is required for GH-induced liver IGF-I gene expression. Endocrinology. 2001, 142: 3836-3841. 10.1210/en.142.9.3836.CrossRefPubMed
57.
Haffner MC, Petridou B, Peyrat JP, Revillion F, Muller-Holzner E, Daxenbichler G, Marth C, Doppler W: Favorable prognostic value of SOCS2 and IGF-I in breast cancer. BMC Cancer. 2007, 7: 136-10.1186/1471-2407-7-136.CrossRefPubMedPubMedCentral
58.
Wang Y, Jiang H: Identification of a distal STAT5-binding DNA region that may mediate growth hormone regulation of insulin-like growth factor-I gene expression. J Biol Chem. 2005, 280: 10955-10963. 10.1074/jbc.M412808200.CrossRefPubMed
59.
Dong J, Tong T, Reynado AM, Rosen JM, Huang S, Li Y: Genetic manipulation of individual somatic mammary cells in vivo reveals a master role of STAT5a in inducing alveolar fate commitment and lactogenesis in the absence of reproductive hormones. Dev Biol. 2010, 346: 196-203. 10.1016/j.ydbio.2010.07.027.CrossRefPubMedPubMedCentral
60.
Iavnilovitch E, Cardiff RD, Groner B, Barash I: Deregulation of Stat5 expression and activation causes mammary tumors in transgenic mice. Int J Cancer. 2004, 112: 607-619. 10.1002/ijc.20484.CrossRefPubMed
61.
Creamer BA, Sakamoto K, Schmidt JW, Triplett AA, Moriggl R, Wagner K-U: Stat5 promotes survival of mammary epithelial cells through transcriptional activation of a distinct promoter in Akt1. Mol Cell Biol. 2010, 30: 2957-2970. 10.1128/MCB.00851-09.CrossRefPubMedPubMedCentral
62.
Santos SJ, Haslam SZ, Conrad SE: Signal transducer and activator of transcription 5a mediates mammary ductal branching and proliferation in the nulliparous mouse. Endocrinology. 2010, 151: 2876-2885. 10.1210/en.2009-1282.CrossRefPubMedPubMedCentral
63.
Srivastava S, Matsuda M, Hou Z, Bailey JP, Kitazawa R, Herbst MP, Horseman ND: Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells. J Biol Chem. 2003, 278: 46171-46178. 10.1074/jbc.M308545200.CrossRefPubMed
64.
Hosui A, Kimura A, Yamaji D, Zhu B-mei, Na R, Hennighausen L: Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-{beta} and STAT3 activation. J Exp Med. 2009, 206: 819-831. 10.1084/jem.20080003.CrossRefPubMedPubMedCentral
65.
Walker SR, Nelson EA, Zou L, Chaudhury M, Signoretti S, Richardson A, Frank DA: Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res. 2009, 7: 966-976. 10.1158/1541-7786.MCR-08-0238.CrossRefPubMed
66.
Vafaizadeh V, Klemmt P, Brendel C, Weber K, Doebele C, Britt K, Grez M, Fehse B, Desrivieres S, Groner B: Mammary epithelial reconstitution with genemodified stem cells assigns roles to Stat5 in luminal alveolar cell fate decisions, differentiation, involution, and mammary tumor formation. Stem Cells. 2010, 28: 928-938.PubMed
67.
Eilon T, Barash I: Different gene-expression profiles for the poorly differentiated carcinoma and the highly differentiated papillary adenocarcinoma in mammary glands support distinct metabolic pathways. BMC Cancer. 2008, 8: 270-10.1186/1471-2407-8-270.CrossRefPubMedPubMedCentral
68.
Nevalainen MT, Xie J, Bubendorf L, Wagner K-U, Rui H: Basal activation of transcription factor signal transducer and activator of transcription (Stat5) in nonpregnant mouse and human breast epithelium. Mol Endocrinol. 2002, 16: 1108-1124. 10.1210/me.16.5.1108.CrossRefPubMed
69.
Oakes SR, Naylor MJ, Asselin-Labat M-L, Blazek KD, Gardiner-Garden M, Hilton HN, Kazlauskas M, Pritchard MA, Chodosh LA, Pfeffer PL, Lindeman GJ, Visvader JE, Ormandy CJ: The Ets transcription factor Elf5 specifies mammary alveolar cell fate. Genes Dev. 2008, 22: 581-586. 10.1101/gad.1614608.CrossRefPubMedPubMedCentral
70.
Humphreys RC, Hennighausen L: Transforming growth factor alpha and mouse models of human breast cancer. Oncogene. 2000, 19: 1085-1091. 10.1038/sj.onc.1203278.CrossRefPubMed
71.
Maroulakou IG, Oemler W, Naber SP, Klebba I, Kuperwasser C, Tsichlis PN: Distinct roles of the three Akt isoforms in lactogenic differentiation and involution. J Cell Physiol. 2008, 217: 468-477. 10.1002/jcp.21518.CrossRefPubMedPubMedCentral
72.
Ke Y, Lesperance J, Zhang EE, Bard-Chapeau EA, Oshima RG, Muller WJ, Feng G-S: Conditional deletion of Shp2 in the mammary gland leads to impaired lobulo-alveolar outgrowth and attenuated Stat5 activation. J Biol Chem. 2006, 281: 34374-34380. 10.1074/jbc.M607325200.CrossRefPubMedPubMedCentral
73.
Edwards GM, Wilford FH, Liu X, Hennighausen L, Djiane J, Streuli CH: Regulation of mammary differentiation by extracellular matrix involves protein-tyrosine phosphatases. J Biol Chem. 1998, 273: 9495-9500. 10.1074/jbc.273.16.9495.CrossRefPubMed
74.
Naylor MJ, Li N, Cheung J, Lowe ET, Lambert E, Marlow R, Wang P, Schatzmann F, Wintermantel T, Schuetz G, Clarke AR, Mueller U, Hynes NE, Streuli CH: Ablation of beta1 integrin in mammary epithelium reveals a key role for integrin in glandular morphogenesis and differentiation. J Cell Biol. 2005, 171: 717-728. 10.1083/jcb.200503144.CrossRefPubMedPubMedCentral
75.
Leonoudakis D, Singh M, Mohajer R, Mohajer P, Fata JE, Campbell KP, Muschler JL: Dystroglycan controls signaling of multiple hormones through modulation of STAT5 activity. J Cell Sci. 2010, 123: 3683-3692. 10.1242/jcs.070680.CrossRefPubMedPubMedCentral
76.
Wu W-J, Lee C-F, Hsin C-H, Du J-Y, Hsu T-C, Lin T-H, Yao T-Y, Huang C-H, Lee Y-J: TGF-beta inhibits prolactin-induced expression of beta-casein by a Smad3-dependent mechanism. J Cell Biochem. 2008, 104: 1647-1659. 10.1002/jcb.21734.CrossRefPubMed
77.
Cocolakis E, Dai M, Drevet L, Ho J, Haines E, Ali S, Lebrun J-J: Smad signaling antagonizes STAT5-mediated gene transcription and mammary epithelial cell differentiation. J Biol Chem. 2008, 283: 1293-1307.CrossRefPubMed
78.
Wang Z, Li G, Tse W, Bunting KD: Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement. Blood. 2009, 113: 4856-4865. 10.1182/blood-2008-09-181107.CrossRefPubMedPubMedCentral
79.
Liu F, Kunter G, Krem MM, Eades WC, Cain JA, Tomasson MH, Hennighausen L, Link DC: Csf3r mutations in mice confer a strong clonal HSC advantage via activation of Stat5. J Clin Invest. 2008, 118: 946-955.PubMedPubMedCentral
80.
Yao Z, Cui Y, Watford WT, Bream JH, Yamaoka K, Hissong BD, Li D, Durum SK, Jiang Q, Bhandoola A, Hennighausen L, O'Shea JJ: Stat5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci USA. 2006, 103: 1000-1005. 10.1073/pnas.0507350103.CrossRefPubMedPubMedCentral
81.
82.
Ren S, Cai HR, Li M, Furth PA: Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene. 2002, 21: 4335-4339. 10.1038/sj.onc.1205484.CrossRefPubMed
83.
Sakamoto K, Triplett AA, Schuler LA, Wagner KU: Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer. Oncogene. 2010, 29: 5359-5369. 10.1038/onc.2010.274.CrossRefPubMedPubMedCentral
84.
Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J, Sauter G, Rui H: Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol. 2004, 22: 2053-2060. 10.1200/JCO.2004.11.046.CrossRefPubMed
85.
Cotarla I, Ren S, Zhang Y, Gehan E, Singh B, Furth PA: Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer. 2004, 108: 665-671. 10.1002/ijc.11619.CrossRefPubMed
86.
Yamashita H, Nishio M, Ando Y, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y, Iwase H: Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Endocr Relat Cancer. 2006, 13: 885-893. 10.1677/erc.1.01095.CrossRefPubMed
87.
Peck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, Pequignot E, Freydin B, Tran TH, Yang N, Rosenberg AL, Hooke JA, Kovatich AJ, Nevalainen MT, Shriver CD, Hyslop T, Sauter G, Rimm DL, Magliocco AM, Rui H: Loss of nuclear localized and tyrosine phosphorylated stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol. 2011, 29: 2448-2458. 10.1200/JCO.2010.30.3552.CrossRefPubMedPubMedCentral
88.
Tran TH, Utama FE, Lin J, Yang N, Sjolund AB, Ryder A, Johnson KJ, Neilson LM, Liu C, Brill KL, Rosenberg AL, Witkiewicz AK, Rui H: Prolactin inhibits BCL6 expression in breast cancer through a Stat5a-dependent mechanism. Cancer Res. 2010, 70: 1711-1721. 10.1158/0008-5472.CAN-09-2314.CrossRefPubMedPubMedCentral
89.
Bogorad RL, Courtillot C, Mestayer C, Bernichtein S, Harutyunyan L, Jomain JB, Bachelot A, Kuttenn F, Kelly PA, Goffin V, Touraine P: Identification of a gainof-function mutation of the prolactin receptor in women with benign breast tumors. Proc Natl Acad Sci USA. 2008, 105: 14533-14538. 10.1073/pnas.0800685105.CrossRefPubMedPubMedCentral
90.
Mohankumar KM, Perry JK, Kannan N, Kohno K, Gluckman PD, Emerald BS, Lobie PE: Transcriptional activation of signal transducer and activator of transcription (STAT) 3 and STAT5B partially mediate homeobox A1-stimulated oncogenic transformation of the immortalized human mammary epithelial cell. Endocrinology. 2008, 149: 2219-2229. 10.1210/en.2007-1320.CrossRefPubMed
91.
Shi Z, Hodges VM, Dunlop EA, Percy MJ, Maxwell AP, El-Tanani M, Lappin TRJ: Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line. Mol Cancer Res. 2010, 8: 615-626. 10.1158/1541-7786.MCR-09-0264.CrossRefPubMed
92.
Sultan AS, Brim H, Sherif ZA: Co-overexpression of Janus kinase 2 and signal transducer and activator of transcription 5a promotes differentiation of mammary cancer cells through reversal of epithelial-mesenchymal transition. Cancer Sci. 2008, 99: 272-279. 10.1111/j.1349-7006.2007.00685.x.CrossRefPubMed
93.
Gutzman JH, Rugowski DE, Nikolai SE, Schuler LA: Stat5 activation inhibits prolactin-induced AP-1 activity: distinct prolactin-initiated signals in tumorigenesis dependent on cell context. Oncogene. 2007, 26: 6341-6348. 10.1038/sj.onc.1210454.CrossRefPubMedPubMedCentral
94.
Barclay JL, Anderson ST, Waters MJ, Curlewis JD: SOCS3 as a tumor suppressor in breast cancer cells, and its regulation by PRL. Int J Cancer. 2009, 124: 1756-1766. 10.1002/ijc.24172.CrossRefPubMed
95.
Yuan T, Wang Y, Zhao ZJ, Gu H: Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and epidermal growth factor receptor signaling in breast cancer cells. J Biol Chem. 2010, 285: 14861-14870. 10.1074/jbc.M109.099879.CrossRefPubMedPubMedCentral
96.
Perotti C, Liu R, Parusel CT, Bocher N, Schultz J, Bork P, Pfitzner E, Groner B, Shemanko CS: Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulation. Breast Cancer Res. 2008, 10: R94-10.1186/bcr2193.CrossRefPubMedPubMedCentral
97.
98.
Sarfstein R, Maor S, Reizner N, Abramovitch S, Werner H: Transcriptional regulation of the insulin-like growth factor-I receptor gene in breast cancer. Mol Cell Endocrinol. 2006, 252: 241-246. 10.1016/j.mce.2006.03.018.CrossRefPubMed
99.
Ciocca DR, Gago FE, Fanelli MA, Calderwood SK: Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: clinical implications. J Steroid Biochem Mol Biol. 2006, 102: 32-40. 10.1016/j.jsbmb.2006.09.008.CrossRefPubMed
Metadata
Title
Signal transducer and activator of transcription 5 as a key signaling pathway in normal mammary gland developmental biology and breast cancer
Authors
Priscilla A Furth
Rebecca E Nakles
Sarah Millman
Edgar S Diaz-Cruz
M Carla Cabrera
Publication date
01-10-2011
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2011
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2921

Other articles of this Issue 5/2011

Breast Cancer Research 5/2011 Go to the issue

Research article

Generation of tumor-initiating cells by exogenous delivery of OCT4transcription factor

Research article

Nondense mammographic area and risk of breast cancer

Research article

Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness

Research article

Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB

Research article

Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts

Review

Minimal residual disease and circulating tumor cells in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits